Excel Dryer Announces New Surface-Mounted, Slimmer Profile ThinAir® Hand Dryer
Excel Dryer, Inc., manufacturer of the finest American made hand dryers for over 50 years, featuring the high-speed, energy-efficient XLERATOR® Hand Dryer, introduces the new ThinAir® Hand Dryer, a high-efficiency surface-mounted model that protrudes no more than 10 cm from the wall. ThinAir dries hands in 15 seconds,* operates on 960 watts and is a quick and easy retrofit solution for any facility looking to save money and easily maintain a cleaner restroom.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151013006503/en/
ThinAir Hand Dryer by Excel Dryer, Inc. (Photo: Business Wire)
“The ThinAir Hand Dryer eliminates the need to recess the dryer into a restroom wall to achieve a protrusion of no more than 10 cm, which is beneficial for facilities with walls that are difficult to modify,” said Excel Dryer Vice President of Marketing, William Gagnon. “ThinAir has a lower cost of ownership than other hand dryers, and is easier to install making it a cost effective and affordable option for facilities looking for reliable performance and high efficiency.”
ThinAir features a slimmer profile, adjustable speed and sound control, on/off heat, an antimicrobial ABS cover and a washable pre-filter to extend the life of the unit. The speed and sound control can adjust the operational sound level from 75 decibels down to 67 decibels, making it one of the quietest dryers on the market. The on/off heat control brings the wattage down from 960 watts to as low as 333 watts with the heat turned off. As a sensor-activated, touch-free hand dryer, ThinAir reduces touch points and decreases the risk of cross-contamination from users contacting potentially unclean surfaces in a restroom. Optional MICROBAN® Antimicrobial Wall Guards protect wall finishes from excess water and are ideal for high-traffic restrooms. Wall Guards are both hygienic and easy to clean.
ThinAir hand dryers can be ordered in 110 to 240 volts in 60 Hz or 50 Hz for distribution worldwide. Excel Dryer manufactures the only hand dryers that are Made in USA Certified®, the first to be GreenSpec® Listed and also qualify for several LEED® v4 Credits and Green Globes to meet corporate or government sustainability goals.
For more information about Excel Dryer, visit exceldryer.com/products_thinair.php.
About Excel Dryer, Inc.
For over 50 years, Excel Dryer has been manufacturing the finest American made hand dryers featuring the XLERATOR ® Hand Dryer. Excel Dryer is a family owned and operated company which revolutionized the industry by inventing the patented XLERATOR technology that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer continues to lead the industry with its expanded product line featuring speed and sound controls, HEPA filtration and custom covers, to design the best hand drying solution for any restroom environment. Excel Dryer products are marketed through an established network of sales representatives who call on more than 4,000 distributors globally for distribution worldwide. Learn more about Excel Dryer at exceldryer.com .
* Dry time based on third party testing performed by SGS International on standard XLERATOR® Hand Dryer/XLERATOReco ® Hand Dryer/ThinAir® Hand Dryer with 0.8 nozzle to less than 0.2g of residual moisture.
For Excel Dryer
Caroline Lee or Michelle Abdow, 413-787-1133
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19 | Pressemelding
Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom